mRNA-1273 Vaccine Against COVID-19
Phase 1 Interim Analysis of Older Adult Cohorts (ages 56-70 and 71+)
August 26, 2020
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning the potential for mRNA-1273 to generate neutralizing antibodies in older adults, the potential for adverse side effects from mRNA-1273, the scaling of manufacturing for mRNA-1273, tolerability, stability and shelf-life of mRNA-1273 under different conditions and temperatures, and the ability to supply doses under certain timeframes. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the ability to manufacture and deliver doses at the scale required by agreements with customers; preclinical and clinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no commercial product using mRNA technology has been approved, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines; despite having ongoing interactions with the U.S. Food and Drug Administration (FDA) or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; potential adverse impacts due to the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.
Phase 1 study of mRNA-1273 vaccine against COVID-19

Presentation of older adult cohorts

• Presentation at Advisory Committee on Immunization Practices (ACIP) meeting

• At the 100 µg dose, mRNA-1273 was generally safe and well-tolerated in all age cohorts

• At the 100 µg dose, mRNA-1273 induced consistently high levels of neutralizing antibody titers in all participants in the 56-70 (n=10) and 71+ age cohorts (n=10); titers were 2-3 fold above those seen in convalescent sera

• mRNA-1273 elicited Th1-biased CD4 T cell responses in the 56-70 and 71+ age cohorts

• Neutralizing antibody titers and T cell responses in the 56-70 and 71+ age cohorts were consistent with those reported in younger adults
**Phase 1 trial overview**

*Led by the National Institutes of Health (NIH)*

**Key objective:**
- To assess the safety, reactogenicity and immunogenicity of mRNA-1273

**Study design:**
- Phase 1, open-label dose ranging clinical trial in healthy adults
- Subjects received an intramuscular (IM) injection (0.5 milliliter [mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be followed through 12 months post second vaccination (Day 394)

**Primary endpoint:**
- Safety and reactogenicity of a 2-dose vaccination schedule of mRNA-1273, given 28 days apart

**Secondary endpoint:**
- Evaluate the immunogenicity to the SARS-CoV-2 S protein following a 2-dose vaccination schedule of mRNA-1273 at Day 57

**Trial progress/details:**
- Original 3 dose cohorts 25 µg, 100 µg and 250 µg (18-55 years old) Day 57 data published in *The New England Journal of Medicine*¹
- Interim analysis of the 100 µg dose for the 56-70 and 71+ age cohorts available today
- 50 µg dose across three age cohorts (18-55, 56-70 and 71+) are fully enrolled

---

100 µg mRNA-1273 well-tolerated across age groups

Phase 1: No Vaccine-Related SAEs Have Been Reported

Solicited Local and Systemic Symptoms Followed for 7 Days Post-vaccination

Majority of symptoms resolved within 2 days, some persisted as long as 5 days

Symptom | Age group² | Vaccination 1 | Vaccination 2 | Grade 1 (mild) | Grade 2 (moderate) | Grade 3 (severe)
--- | --- | --- | --- | --- | --- | ---
Any systemic symptom | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Arthralgia | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Fatigue | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Fever¹ | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Chills | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Headache | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |

Symptom | Age group² | Vaccination 1 | Vaccination 2 | Grade 1 (mild) | Grade 2 (moderate) | Grade 3 (severe)
--- | --- | --- | --- | --- | --- | ---
Myalgia | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Nausea | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Any local symptom | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Erythema, redness measurement | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Induration/swelling measurement | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |
Pain | 18-55 | | | | | |
| | 56-70 | | | | | |
| | 71+ | | | | | |

1. Fever percentages reflect the number of subjects with at least one measurement available in the data system as the denominator. This denominator may differ from other systemic symptoms, which are solicited in-clinic at the post-dose assessment.

2. 18-55: N=15; 56-70: N=10; 71+: N=10; N = All subjects receiving Dose 1 with any solicited event data recorded in the database.

Binding antibodies comparable across age groups

S-2P binding antibodies (ELISA) - 100 μg at Day 1 and Day 29

- 100 μg two-dose series seroconverted all participants after the first vaccination
- After the first vaccination, AUC for all age groups exceeded the median of convalescent sera
- After two vaccinations, all age groups are equivalent to high-titer convalescent sera (i.e., upper quartile)
Distribution of antibody titers in pseudovirus neutralization assay comparable across age groups

*Pseudovirus neutralization assay titers (ID$_{50}$) - 100 μg at Day 1 and Day 29*

- After second vaccination, pseudovirus neutralization responses were detected in all participants
- Pseudovirus neutralization titers were comparable across age groups
- Pseudovirus neutralization titer for 56-70 and 71+ YOA above convalescent sera median titer at Day 57

**Range of convalescent sera**

- 18 – 55 years
  - D57 GMT: 267
  - 95% CI: 186, 385
- 56 – 70 years
  - D57 GMT: 324
  - 95% CI: 212, 496
- 71+ years
  - D57 GMT: 242
  - 95% CI: 147, 399
mRNA-1273 elicited Th1-biased CD4 T cell responses in all participants

Th1 CD4+ T cell response, S1 peptide pool (100 μg at Day 1 and 29)

- Vaccination with 100 μg mRNA-1273 led a Th1-biased CD4+ T-cell response across all age groups.
- Th2 phenotype was rare (data not shown).


Interim Immunogenicity Report
Manufacturing and distribution update

Key takeaways

• Collaboration with partners Lonza, Catalent and ROVI

• On track to supply 500 million to 1 billion doses per year at the Phase 3 selected dose of 100 µg

• Current storage and distribution conditions at -20°C/−4°F Fahrenheit with point of care temperature at normal refrigerated conditions (2-8°C/36-46°F Fahrenheit)\(^1\)

• No onsite dilution or special handling needed

1. Continuing to gather real-time stability data
mRNA-1273 vaccine against COVID-19

• Phase 1 clinical data
  – Neutralizing antibody titers were observed in 100% of evaluated participants across all age groups
  – In the pseudovirus (ID$_{50}$) neutralization assay, at the 100 µg dose, mRNA-1273 induced consistently high levels of neutralizing antibody titers in all participants in the young adult and older adult cohorts
  – In the live SARS-CoV-2 (PRNT$_{80}$) neutralization assay in the younger adult cohort, the Day 43 geometric mean titer levels at the Phase 3 selected dose of 100 µg were above those seen in reference convalescent sera

• Nonhuman primate data publication
  – Two-dose vaccination schedule of mRNA-1273 led to rapid protection against SARS-CoV-2 infection in both the lungs and nose of non-human primates

• COVE Phase 3 study of mRNA-1273
  – As of Tuesday, August 25th, 15,239 participants have been enrolled

3. Moderna COVE study: https://www.modernatx.com/cove-study
Modernma’s mRNA platform

mRNA

Chemistry

Sequence engineering

Targeting elements

Delivery

Chemistry

Composition

Surface properties

Manufacturing Process

mRNA

LNP

Prophylactic vaccines

Cancer vaccines

Intratumoral immuno-oncology

Localized regenerative therapeutics

Systemic secreted & cell surface therapeutics

Systemic intracellular therapeutics

Modernma Annual Science Day Presentation, 02 Jun 2020
https://investors.modernatx.com/static-files/5ded4992-e730-4b41-b756-db53-c9ab-9a9b
Our mission
To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Please join us virtually for **R&D Day**

**Thursday, Sept. 17th, 2020**

8:00 AM – 12:30 PM ET

Webcast link will be available on our website